Neuraxis (NRXS) Return on Assets (2023 - 2025)

Neuraxis (NRXS) posted Return on Assets of 0.01% for Q4 2025, down 10.39% sequentially from 0.01% in Q3 2025, and up 1.0% YoY from 0.01% in Q4 2024.

Neuraxis (NRXS) Return on Assets (2023 - 2025) Analysis & Trends

Neuraxis has reported Return on Assets for 3 years, with the latest figure at 0.01% in Q4 2025.

Quarterly Return on Assets rose 1.0% year-over-year to 0.01% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 0.01% (up 1.0% YoY) and the FY2025 annual result came in at 0.01%, up 1.0% from the prior year.
Return on Assets retreated to 0.01% in Q4 2025 per NRXS's latest filing, from 0.01% in the prior quarter.
Over five years, Return on Assets peaked at 0.01% in Q3 2025 and troughed at 0.11% in Q1 2024.
A 3-year average of 0.04% and a median of 0.03% in 2024 frame the typical range for Return on Assets.
The sharpest annual moves came in 2024 and 2025: Return on Assets changed 0 bps in 2024, then climbed 9 bps in 2025.
Over 3 years, Return on Assets stood at 0.08% in 2023, then surged by 68 bps to 0.03% in 2024, then soared by 48 bps to 0.01% in 2025.
According to Business Quant data, Return on Assets over the past three periods registered 0.01%, 0.01%, and 0.01% for Q4 2025, Q3 2025, and Q2 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROA (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	0.00%
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	0.00%
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	-
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	0.00%
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	0.00%
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	0.00%
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	0.00%
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	0.00%
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	0.00%
10	Neuraxis	75.51 Mn	67.18 Mn	-	-

Download Data